Repligen

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell Repligen and other ETFs, options, and stocks.

About RGEN

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. 

CEO
Olivier Dominique Loeillot
CEOOlivier Dominique Loeillot
Employees
2,000
Employees2,000
Headquarters
Waltham, Massachusetts
HeadquartersWaltham, Massachusetts
Founded
1981
Founded1981
Employees
2,000
Employees2,000

RGEN Key Statistics

Market cap
7.44B
Market cap7.44B
Price-Earnings ratio
163.53
Price-Earnings ratio163.53
Dividend yield
Dividend yield
Average volume
1.38M
Average volume1.38M
High today
$138.13
High today$138.13
Low today
$131.82
Low today$131.82
Open price
$138.13
Open price$138.13
Volume
1.34M
Volume1.34M
52 Week high
$175.77
52 Week high$175.77
52 Week low
$100.99
52 Week low$100.99

Stock Snapshot

As of today, Repligen(RGEN) shares are valued at $131.96. The company's market cap stands at 7.44B, with a P/E ratio of 163.53.

On 2026-07-25, Repligen(RGEN) stock traded between a low of $131.82 and a high of $138.13. Shares are currently priced at $131.96, which is +0.1% above the low and -4.5% below the high.

Repligen(RGEN) shares are trading with a volume of 1.34M, against a daily average of 1.38M.

During the past year, Repligen(RGEN) stock moved between $100.99 at its lowest and $175.77 at its peak.

During the past year, Repligen(RGEN) stock moved between $100.99 at its lowest and $175.77 at its peak.

RGEN News

Simply Wall St 6h
BioLife Solutions Faces Fairness Probes After Repligen Agrees To Buy It

Repligen has entered into a definitive agreement to acquire BioLife Solutions, the cell therapy tools company traded as NasdaqCM:BLFS. Following the deal annou...

BioLife Solutions Faces Fairness Probes After Repligen Agrees To Buy It
Nasdaq 18h
RGEN June 2027 Options Begin Trading

Investors in Repligen Corp. (Symbol: RGEN) saw new options begin trading today, for the June 2027 expiration. One of the key inputs that goes into the price an...

RGEN June 2027 Options Begin Trading
Zacks 2d
Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Zacks Investment Research

...

Repligen to Expand Cell Therapy Capabilities With BioLife Buyout - Zacks Investment Research

Analyst ratings

86%

of 22 ratings
Buy
86.4%
Hold
13.6%
Sell
0%

More RGEN News

Simply Wall St 2d
Is Repligen Still Undervalued Following Its $1.5b BioLife Deal?

Repligen (RGEN) has agreed to acquire BioLife Solutions in a roughly $1.5 billion deal, a move that immediately shifts investor focus to how a larger cell thera...

Is Repligen Still Undervalued Following Its $1.5b BioLife Deal?
Benzinga 3d
Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition

Repligen Expands Into Cell Therapy The acquisition aims to capitalize on the rapidly expanding cell therapy sector. Industry commercial revenues are forecast t...

Repligen Strengthens Cell Therapy Portfolio With BioLife Acquisition
TipRanks 3d
Repligen to Acquire BioLife, Expanding Cell Therapy Reach

Unlock powerful investing tools with TipRanks Premium to make smarter, more confident investment decisions Subscribe to TipRanks Smart Investor Newsletter, and...

TipRanks 3d
Repligen to acquire BioLife Solutions for $31 per share, or $1.5B

Repligen (RGEN) and BioLife Solutions (BLFS) announced they have entered into a definitive agreement under which Repligen, subject to customary closing conditio...

People also own

Based on the portfolios of people who own RGEN. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.